RESEARCH

Ionizing radiations induce shared epigenomic signatures unraveling adaptive mechanisms of cancerous cell lines with or without methionine dependency

Youssef Siblini1, Céline Chéry1,2,3, Pierre Rouyer1, Jérémie Raso1, Amélie Julien1, Sébastien Hergalant1, Aurélie François4, Lina Bezdetnaya4,5, Guillaume Vogin6, Jean-Louis Guéant1,2,3* and Abderrahim Oussalah1,2,3*

Abstract

Background: Although radiation therapy represents a core cancer treatment modality, its efficacy is hampered by radioresistance. The effect of ionizing radiations (IRs) is well known regarding their ability to induce genetic alterations; however, their impact on the epigenome landscape in cancer, notably at the CpG dinucleotide resolution, remains to be further deciphered. In addition, no evidence is available regarding the effect of IRs on the DNA methylome profile according to the methionine dependency phenotype, which represents a hallmark of metabolic adaptation in cancer.

Methods: We used a case–control study design with a fractionated irradiation regimen on four cancerous cell lines representative of HCC (HepG2), melanoma (MeWo and MeWo-LC1, which exhibit opposed methionine dependency phenotypes), and glioblastoma (U251). We performed high-resolution genome-wide DNA methylome profiling using the MethylationEPIC BeadChip on baseline conditions, irradiated cell lines (cumulative dose of 10 Gy), and non-irradiated counterparts. We performed epigenome-wide association studies to assess the effect of IRs and methionine-dependency-oriented analysis by carrying out epigenome-wide conditional logistic regression. We looked for epigenome signatures at the locus and single-probe (CpG dinucleotide) levels and through enrichment analyses of gene ontologies (GO). The EpiMet project was registered under the ID#AAP-BMS_003_211.

Results: EWASs revealed shared GO annotation pathways associated with increased methylation signatures for several biological processes in response to IRs, including blood circulation, plasma membrane-bounded cell projection organization, cell projection organization, multicellular organisinal process, developmental process, and animal organ morphogenesis. Epigenome-wide conditional logistic regression analysis on the methionine dependency phenotype highlighted several epigenome signatures related to cell cycle and division and responses to IR and ultraviolet light.

Conclusions: IRs generated a variation in the methylation level of a high number of CpG probes with shared biological pathways, including those associated with cell cycle and division, responses to IRs, sustained angiogenesis, tissue invasion, and metastasis. These results provide insight on shared adaptive mechanisms of the epigenome in cancerous cell lines in response to IR. Future experiments should focus on the tryptic association between IRs, the initiation...
Introduction

Epigenome alterations, including modifications of DNA methylation, represent a hallmark of cancer initiation, progression, metastasis, and recurrence [1–5]. Cancerous cell lines use epigenomic reprogramming to develop new strategies against anticancer treatments, including radiation therapy [1]. DNA methylation requires S-adenosyl methionine (SAM) as a methyl donor for which methionine represents the immediate metabolic precursor. Dependency to methionine, also called methionine dependency, is a metabolic adaptation that occurs in association with cancerous transformation, and its interaction with epigenetic modifications is increasingly recognized as a driver of tumorigenesis [2, 4, 6–8]. In this context, epigenetic modifications have been hypothesized as key drivers for tumor aggressiveness, with resistant phenotype to conventional chemo- and radiotherapy and an ability to develop metastases [5].

Radiation therapy represents a core modality of cancer treatment [9]. For instance, it is indicated in newly diagnosed or recurrent glioblastoma [10–12] and has gained interest in recent years in the therapeutic algorithm of hepatocellular carcinoma (HCC), notably through stereotactic body radiation therapy [13–16]. In the case of cutaneous malignant melanoma, radiation therapy is not recommended in current guidelines; however, numerous studies reported its efficacy, notably in the setting of elective adjuvant irradiation for eradicating subclinical...
nodal metastases [17]. Radioresistance is a leading cause of cancer progression [18]. Ionizing radiations (IRs) are well known for their ability to induce cellular stress with subsequent alterations in several biological functions, including cellular stress response, cell signaling, DNA synthesis and repair, cell cycle and differentiation, and cell adhesion [19–24].

The effect of IRs is well known regarding their ability to induce genetic alterations [25]. Besides, epigenome alterations have been hypothesized as a potential contributing factor to radioresistance, notably through DNA methylation, histone modification, and chromatin remodeling, which may induce transcriptional reprogramming that enables cells to avoid IR effects [18, 26, 27]. Rodent animal models have shown that IRs affect DNA and histones’ methylation in several organs such as the liver, bone marrow, thymus, and spleen [28]. However, the effect of IRs on epigenetic alterations in cancer, notably at a nucleotide resolution level (CpG dinucleotide), remains to be further deciphered [25].

To date, data are sparse regarding the effect of IRs on the epigenomic landscape of established cancerous cell lines, notably following a fractionated irradiation regimen. Moreover, no work has systematically evaluated the impact of IRs at a nucleotide resolution level using a standardized protocol of fractionated irradiation using multiple cancerous cell lines. In addition, no data have been reported regarding specific epigenome signatures, considering the methionine dependency phenotype, which represents a hallmark of metabolic adaptation in cancer [6–8].

To address this knowledge gap, we used four cancerous cell lines to infer potential epigenomic alterations that IRs could induce in HCC, glioblastoma, and melanoma. HCC and glioblastoma were used as an example of cancer treatable by IRs and melanoma as an example of cancer with no indication of IR according to current guidelines. We were able to identify shared annotation pathways for epigenomic signatures associated with and exposure to IR. Furthermore, we performed epigenome-wide conditional analyses according to methionine dependency phenotype and highlighted several epigenome signatures related to cell division and response to IR.

Methods

Design of the EpiMet project, oversight, and study aims

The EpiMet project was designed to assess the effect of IR, as a cellular stress model, on the epigenome landscape of cancerous cell lines using an EWAS approach. We also looked for potentially contrasted epigenome signatures considering the methionine dependency phenotype using well-phenotyped cell lines. For this purpose, we used four cell lines and three cancer models: HCC, melanoma, and glioblastoma. The EpiMet project was declared at the University of Lorraine (Research Pole of Biology, Medicine, and Health Sciences) and registered under the ID #AAP-BMS_003_211.

Cell lines and cell culture procedures

We cultivated the human HCC HepG2 (ATCC®) cell lines in Dulbecco’s modified Eagle’s medium (DMEM) (Sigma–Aldrich, Saint-Quentin-Fallavier, France) supplemented with 10% volume per volume of heat-inactivated fetal bovine serum (FBS) (Sigma–Aldrich), 1% glutamine (Sigma–Aldrich), and 1% penicillin–streptomycin (P/S) (Sigma–Aldrich). We cultivated the human melanoma cell lines (MeWo [ATCC®], MeWo-LC1 [Dr. Robert Liteplo, University of Ottawa, Ottawa, Ontario]) in DMEM supplemented with 10% volume per volume of FBS, 2% glutamine, and 1% P/S. We cultivated the human glioblastoma cell line U251 (European Collection of Authenticated Cell Cultures [ECACC]) in DMEM supplemented with 10% volume per volume of heat-inactivated FBS, 1% non-essential amino acid (NEAA) (Sigma-Aldrich), 1% glutamine, 1% pyruvate (Sigma–Aldrich), and 1% P/S. All the cells were incubated in a humidified atmosphere with 5% CO2 at 37°C.

Experimental design, cell line irradiation, and cell material

We used a case–control study design with a fractionated irradiation regimen on four cancerous cell lines. In the irradiation arm, the cells were exposed to four IR doses at 2.5 Gy per irradiation at a one-week interval, totaling a cumulative dose of 10 Gy. In the control arm, cell lines were not irradiated and were maintained in similar conditions for the same study period. All cells were maintained in standard culture conditions with a renewal of culture media two times a week. To perform DNA methylome profiling, we prepared flash-frozen cell pellets from irradiated cell lines (‘End_Irradiation’) one week after the fourth irradiation and their non-irradiated counterparts (‘End_No irradiation’) on the same day. We also prepared flash-frozen cell pellets from baseline conditions for each cell line (‘Baseline’) before the initiation of the study. All experiments were performed in biological triplicate, totaling 36 cell flasks (nine flasks per cell line: three Baseline, three End_Irradiation, three End_No irradiation). We performed cell line irradiation at the Department of Radiation Oncology of the Lorraine Institute of Oncology (Vandoeuvre-lès-Nancy, France). The cells were irradiated in the plateau growth phase to avoid any artifacts resulting from the cell cycle. Irradiation was performed on a 6-MeV X-ray linear accelerator (Clinac 2100, Varian, Palo Alto, USA) (see Graphical Abstract).
DNA methylation analyses

We carried out bisulfite conversion of 600 ng of DNA extracted from cell lines using the EZ DNA Methylation kit (Zymo Research, Proteigene, Saint-Marc, France). The genome-wide profiling of DNA methylation was determined using the Infinium MethylationEPIC BeadChip array (Illumina, Paris, France) at the Functional Genomics Facility of the INSERM unit UMR_S 1256 (NGERE, Vandoeuvre-lès-Nancy, France). The Infinium MethylationEPIC BeadChip provides coverage of >850,000 CpG probes in enhancer regions, gene bodies, promoters, and CpG islands. The arrays were scanned on an Illumina iScan® system, and raw methylation data were extracted using Illumina’s Genome Studio methylation module. For each CpG probe, the methylation level was described as a $\beta$ value, ranging between 0 (fully unmethylated CpG probe) and 1 (fully methylated CpG probe). Background correction and normalization were implemented using the SWAN method (R Package Minfi) [29]. Probe annotation information, including sequence and chromosome location for the Infinium MethylationEPIC BeadChip array, was retrieved from the Infinium MethylationEPIC v1.0 B5 Manifest File.

Quality controls of methylome array data and bioinformatics analyses

We visually inspected the whole-genome distribution of the CpG probes according to their $\beta$ value. We performed primary component analysis (PCA) to assess the clustering of methylation profiles according to the whole methylation landscape of the studied cell lines. The top ten principal components (eigenvectors, EV) were calculated with their respective eigenvalue. PCA plots were used to report on the three top eigenvalues. We performed our analytical approach using a sequential approach. In step #1, we compared the epigenome landscape between ‘Baseline’ and ‘End_No irradiation’ conditions to assess whether the maintenance of cell lines affected DNA methylation. In step #2, we performed an EWAS that pooled ‘Baseline’ and ‘End_No irradiation’ conditions to compare them with the ‘End_Irradiation’ condition. The aim of step #2 was to assess whether the exposure to a cumulative dose of 10 Gy affected the DNA methylation landscape of the studied cell lines. In this step, we performed a sensitivity analysis EWAS by removing the ‘Baseline’ condition from the control group to compare the ‘End_Irradiation’ versus ‘End_No irradiation’ condition. In step #3, we performed the same analysis described in step #2 on each of the four cell lines. Finally, in step #4, we assessed using enrichment analyses the gene ontology (GO) pathways significantly associated with exposure to IRs and looked for shared GO annotations between the studied cell lines. In each EWAS (steps #1–3), we compared the mean $\beta$ values of each CpG probe between the two subgroups using the $t$-test with Bonferroni correction. Output data included the mean $\beta$ values in each subgroup, the difference of $\beta$ values, the nominal $P$-value, and the Bonferroni corrected $P$-value. To assess the effect of IRs on the epigenome landscape with respect to the methionine dependency phenotype, we performed conditional logistic regression EWAS using the methylation profiles from methionine-dependent cell lines (MeWo-LC1) and their methionine-independent counterpart (MeWo) [30]. We used the ‘End_Irradiation’ as the dependent variable and the methionine-dependent phenotype as the conditional covariate. EWAS results were reported using an epi-Manhattan plot. We performed enrichment analyses on CpG probes exhibiting increased or decreased methylation signatures (difference of $\beta$ values $>0.1$ or $< -0.1$, respectively) using the GO Enrichment Analysis tool [31]. For the conditional logistic regression EWAS, we performed enrichment analyses on the CpG probes with beta regression coefficient values $>200$ or $<-200$. We used PANTHER ‘GO-Slim Biological Process’ and ‘GO-biological process complete’ annotation datasets and the REVIGO tool to summarize and visualize statistically significant GO terms based on their calculated metrics (uniqueness and dispensability) [32]. We identified top enriched GO annotations using quantile–quantile plot representation. All statistical analyses were performed using the SNP and Variation Suite (v8.8.1; Golden Helix, Inc., Bozeman, MT, USA) and MedCalc, version 19.5.3 (MedCalc Software, Ostend, Belgium).

Results

Principal component analyses for DNA methylation profile assessment

We performed DNA methylation profiling of the 36 samples corresponding to nine flasks (three samples of the conditions ‘Baseline’, ‘End_Irradiation’, and ‘End_No irradiation’) for each of the four studied cell lines. All methylation profiles passed quality checks and exhibited a valid $\beta$ value density distribution (Additional file 1: Figure S1). In PCA on genome-wide DNA methylation profiles, we found a clustered distribution according to the cell line type (Fig. 1A). Cell line clustering was associated with the third PCA vector (EV = 0.32). In both 3-D and 2-D visual inspection of the PCA plots, we found no systematic clustering of DNA methylation profiles between ‘Baseline’ and ‘End_No irradiation’ conditions (Additional file 2: Figure S2, Additional file 3: Figure S3). Furthermore, we found no significant clustering of DNA methylation profiles according to the irradiation status (Fig. 1B, Additional file 3: Figure S3).
Epigenome-wide association studies

We found no statistically significant locus or CpG probe in the EWAS that compared ‘Baseline’ and ‘End_No irradiation’ conditions (Fig. 2A). This allowed us to pool both conditions and compare them with the ‘End_Irradiation’ condition in the whole and subgroup analyses according to cell line type. In the EWAS that assessed the effect of IRs on individual cell types, we found no statistically significant CpG (Fig. 3, Additional file 6: Table S2, Additional file 7: Table S3, 8: Table S4, Additional file 9: Table S5). When we compared the EWAS subanalyses, we found no shared CpG probes exhibiting a difference of $\beta$ values $>0.1$ (Fig. 4A) or $<-0.1$ (Fig. 4B) between the four cell lines. In the conditional logistic regression EWAS that looked for specific epigenome signatures considering the methionine dependency phenotype, we found no statistically significant locus or CpG probe at the genome-wide level (Additional file 10: Figure S4).

Enrichment analyses

Enrichment analyses that used the CpG probes exhibiting a difference of $\beta$ values $>0.1$ or $<-0.1$ found no statistically significant GO annotation when all cell lines were considered together (Additional file 11: Table S6a,b). However, when cell lines were considered separately, we found significantly enriched GO annotations on CpG probes that exhibited a $\beta$ values difference $>0.1$ (increase in methylation level) among HepG2 and MeWo-LC1 cell lines (Fig. 5A and Additional file 11: Table S6c–f) and for CpG probes that exhibited a $\beta$ values difference $<-0.1$ (decrease in methylation level) among HepG2, MeWo-LC1, and U251 cell lines (Fig. 5B and 11: Table S6g–j). Importantly, we found 14 shared GO annotation pathways between HepG2 and MeWo-LC1 cell lines in association with CpG probes with an increased methylation level (Fig. 5A and Additional file 12: Figure S5) with significantly correlated enrichment folds (Spearman's coefficient of rank correlation $[\rho] = 0.825$ (95% CI, 0.522 to 0.943); $P < 0.001$) for the following main annotations: blood circulation, plasma membrane-bounded cell projection organization, and cell projection organization (Table 1; Fig. 6A). Similarly, we found mirrored results with shared GO annotation pathways between HepG2, MeWo-LC1, and U251 cell lines in association with CpG probes with a decreased methylation level (Fig. 5B and Additional file 12: Figure S5) with significantly correlated enrichment folds ($[\rho] = 1$; $P < 0.0001$) (Fig. 6B), including regulation of plasma membrane-bounded cell projection organization and regulation of cell projection organization (Table 2).

In conditional logistic regression EWAS that compared methionine-dependent MeWo-LC1 cells to their non-methionine dependent mother cells MeWo, the enrichment analyses performed on the CpG probes with beta regression coefficient values $>200$ highlighted several
Fig. 2  Epi-Manhattan plot reporting the results of the epigenome-wide association study that compared 'Baseline' versus 'End_No irradiation' (panel A) and 'End_Irradiation' versus (Baseline/End_No irradiation) (panel B).

Table 1  Shared gene ontology annotations for enrichment analyses on CpG probes that exhibited a β values difference > 0.1 before and after ionizing radiation of HepG2 and MeWo-LC1 cell lines

| GO biological process complete | HepG2* | MeWo-LC1* |
|-------------------------------|--------|-----------|
|                               | FE     | P-value   | FDR, P-value | FE     | P-value   | FDR, P-value |
| Blood circulation (GO:0008015) | 3.22  | 2.22 x 10^{-3} | 2.34 x 10^{-2} | 2.33  | 7.49 x 10^{-5} | 1.62 x 10^{-2} |
| Animal organ morphogenesis (GO:0009887) | 2.34  | 1.19 x 10^{-5} | 1.71 x 10^{-2} | 1.97  | 1.58 x 10^{-6} | 8.04 x 10^{-4} |
| Plasma membrane-bounded cell projection organization (GO:0120036) | 2.26  | 3.86 x 10^{-6} | 7.63 x 10^{-3} | 1.73  | 2.98 x 10^{-5} | 8.27 x 10^{-3} |
| Cell projection organization (GO:0030030) | 2.23  | 5.33 x 10^{-6} | 8.42 x 10^{-3} | 1.72  | 2.86 x 10^{-5} | 8.07 x 10^{-3} |
| Cell development (GO:0048468) | 1.95  | 2.02 x 10^{-5} | 2.45 x 10^{-2} | 2.06  | 3.40 x 10^{-12} | 9.56 x 10^{-9} |
| Anatomical structure morphogenesis (GO:0009653) | 1.94  | 7.92 x 10^{-7} | 2.50 x 10^{-3} | 1.82  | 1.49 x 10^{-10} | 1.96 x 10^{-7} |
| Nervous system development (GO:0007399) | 1.86  | 4.60 x 10^{-8} | 8.08 x 10^{-3} | 1.94  | 1.67 x 10^{-13} | 3.31 x 10^{-10} |
| Cell differentiation (GO:003054) | 1.58  | 1.90 x 10^{-5} | 2.51 x 10^{-2} | 1.75  | 9.46 x 10^{-16} | 2.99 x 10^{-12} |
| Cellular developmental process (GO:0048869) | 1.58  | 2.13 x 10^{-5} | 2.40 x 10^{-2} | 1.75  | 6.11 x 10^{-16} | 2.41 x 10^{-12} |
| System development (GO:0048731) | 1.56  | 2.62 x 10^{-6} | 6.89 x 10^{-3} | 1.64  | 8.72 x 10^{-15} | 1.97 x 10^{-11} |
| Multicellular organism development (GO:0007275) | 1.55  | 4.60 x 10^{-7} | 1.82 x 10^{-3} | 1.61  | 5.24 x 10^{-16} | 2.76 x 10^{-12} |
| Anatomical structure development (GO:0048856) | 1.55  | 1.51 x 10^{-7} | 1.19 x 10^{-3} | 1.59  | 9.01 x 10^{-17} | 7.12 x 10^{-13} |
| Developmental process (GO:0032502) | 1.51  | 2.22 x 10^{-7} | 1.17 x 10^{-3} | 1.59  | 5.53 x 10^{-19} | 8.74 x 10^{-15} |
| Multicellular organismal process (GO:0032501) | 1.45  | 1.10 x 10^{-7} | 1.73 x 10^{-3} | 1.46  | 1.64 x 10^{-15} | 4.33 x 10^{-12} |

FE: fold enrichment; DFR: false discovery rate

* No significant GO annotation was found for the CpG probes that exhibited a β values difference > 0.1 before and after ionizing radiation for MeWo and U251 cell lines
pathways, including cell division and responses to IR and ultraviolet light (Table 3, Fig. 7, and Additional file 13: Table S7 a). Conversely, enrichment analyses performed on the CpG probes with beta regression coefficient values $< -200$ highlighted pathways related to cell cycle,
cell division, and DNA damage (Table 4, Fig. 8, and Additional file 13: Table S7 b).

**Discussion**

In the EpiMet study, we assessed the effect of a fractionated regimen of IRs on the epigenome landscape of cancerous cell lines representative of leading causes of cancer incidence and mortality worldwide, including HCC, cutaneous melanoma, and glioblastoma, with a cumulative incidence of over one million new cases diagnosed in 2020 [33]. HCC is the most common primary malignant tumor of the liver [34–36], glioblastoma is the most common and most aggressive malignant primary brain tumor [37], and cutaneous malignant melanoma has an increasing incidence worldwide.
Using an original approach through a case–control study design and four cancerous cell lines (HepG2, MeWo, MeWo-LC1, and U251), we provided better insight at a high-resolution scale on the DNA methylobe variations in association with IRs. While we did not find monogenic epigenome signatures in association with exposure to IRs, we identified significant enrichments in CpG probes exhibiting increased or decreased methylation levels (difference of $\beta$ values > 0.1 or < −0.1, respectively) in association with exposure to IRs that were consistent with epigenomic adaptive mechanisms involving sustained angiogenesis, tissue invasion, and

![Venn diagram](image_url)

**Fig. 5** A Venn diagram illustrating the shared GO annotation pathways between HepG2 and MeWo-LC1 cell lines in association with CpG probes with an increased methylation level; B Venn diagram illustrating the shared GO annotation pathways between HepG2, MeWo-LC1, and U251 cell lines in association with CpG probes with a decreased methylation level.
metastasis. The enrichment folds for the shared epigeneomic signatures were found to be highly correlated across cell lines. In addition, we highlighted several epigeneomic signatures related to cell division and response to IRs in association with the methionine dependency phenotype that we addressed using two melanoma cell lines with opposite methionine dependency phenotypes.

Despite unaltered DNA sequences, epigenetic alterations can alter gene expression and cell functions [38, 39]. DNA methylation alterations represent a dynamic process described under physiological and pathological conditions, including aging, cancer, complex phenotype diseases, and inherited disorders [40–42]. IRs represent a well-defined experimental model of cellular stress [19–24]. DNA methylation has been shown to vary in response to cellular stress conditions [43–45]. Mitochondrial dysfunction, induced by cellular stress, triggers a methylation-dependent pro-survival response with enhanced DNA methylation of tumor suppressor genes and pathways involved in cell survival regulation [45].

Few studies have assessed the effect of IRs on cancerous cell lines, and no study assessed the methylome landscape using the high-density EPIC BeadChip for methylome profiling. A study on the MDA-MB-231 cell line corresponding to metastatic mammary adenocarcinoma assessed the effect of IRs at a unique irradiation dose of 2 or 6 Gy [46]. The DNA methylome profiling assessed by the Infinium HumanMethylation450 BeadChip (M450k array) demonstrated enrichment in GO annotations related to cell cycle, DNA repair, and apoptosis pathways [46]. A comparative analysis of the methylome profile of radiosensitive (SCC-61) and radioresistant (rSCC-61) human squamous cell carcinoma cell lines (head and neck squamous cell cancer) reported an enrichment in glucocorticoid receptor signaling, fatty acid α-oxidation, and cell cycle regulation as top canonical pathways associated with radiation resistance [47]. A recent study investigated the DNA methylation alterations following IRs of glioma stem cells using the M450k array after repeated doses of 2 or 4 Gy using two regimens of 3 or 15 fractions [48]. The DNA methylome signatures were assessed 14 days after the last irradiation. No significant DNA methylation alterations were observed in cell lines that received few fractions of radiations [48]. Conversely, higher radiation doses induced a variation in DNA methylation level at numerous CpG sites whose annotations potentially reflect a cellular response to radiation stress [48].

To date, no study has assessed the DNA methylome alterations in association with IRs using a well-pheno-typed cellular model for methionine dependency in cancer. We performed methionine-dependency-oriented analysis by carrying out epigenome-wide conditional logistic regression analysis and combining epigenome experiments from two cancerous cell lines with mirrored methionine dependency phenotypes (i.e., MeWo-LC1 cell line being methionine dependent and which derives from the methionine-independent MeWo cell line) [30]. Interestingly, we found enrichment in epigenome signatures on loci associated with cell cycle and division, responses to IR and ultraviolet light, and DNA damage.

The present study has several strengths. First, we used an original case–control study design on several
Table 2 Shared gene ontology annotations for enrichment analyses on CpG probes that exhibited a β values difference < −0.1 before and after ionizing radiation of HepG2, MeWo-LC1, and U251 cell lines

| GO biological process complete | HepG2* | MeWo-LC1* | U251* |
|-------------------------------|--------|-----------|-------|
| Regulation of neuron projection development (GO:0010975) | 2.03  | 4.69 × 10⁻⁶ | 1.35 × 10⁻⁴ |
| Response to ionizing radiation (GO:0010212) | 1.94  | 1.05 × 10⁻⁵ | 1.84 × 10⁻² |
| Response to UV (GO:0009411) | 2.05  | 1.58 × 10⁻⁴ | 2.28 × 10⁻⁵ |
| Peripheral nervous system development (GO:0007422) | 1.92  | 6.50 × 10⁻¹⁷ | 2.33 × 10⁻⁴ |
| Centrosome duplication (GO:0051298) | 1.97  | 2.76 × 10⁻¹⁷ | 1.25 × 10⁻⁴ |
| Centrosome cycle (GO:0007098) | 1.92  | 6.05 × 10⁻¹² | 2.33 × 10⁻⁴ |
| Microtubule organizing center organization (GO:0031023) | 1.92  | 6.05 × 10⁻¹⁷ | 2.33 × 10⁻⁴ |
| Nervous system development (GO:0007399) | 1.63  | 6.94 × 10⁻¹² | 1.22 × 10⁻⁴ |
| Nervous system development (GO:0031344) | 1.63  | 6.94 × 10⁻¹² | 1.22 × 10⁻⁴ |
| Microtubule organizing center organization (GO:00031023) | 1.63  | 6.94 × 10⁻¹² | 1.22 × 10⁻⁴ |

FE: fold enrichment; DFR: false discovery rate

*No significant GO annotation was found for the CpG probes that exhibited a β values difference < −0.1 before and after ionizing radiation for MeWo cell line

Table 3 Top enriched gene ontology annotations on CpG probes with beta regression coefficient values > 200 in association with ionizing radiations using conditional logistic regression EWAS on the methionine dependency phenotype

| GO biological process complete | CLR-EWAS for the methionine dependency phenotype (MeWo-LC1 vs. MeWo) |
|-------------------------------|---------------------------------------------------------------|
|                               | FE* | P-value | FDR, P-value |
| Centrosome duplication (GO:0051298) | 3.16 | 1.05 × 10⁻⁴ | 7.80 × 10⁻¹³ |
| Centrosome cycle (GO:0007098) | 2.20 | 2.11 × 10⁻⁴ | 1.41 × 10⁻² |
| Peripheral nervous system development (GO:0007422) | 2.17 | 4.85 × 10⁻⁴ | 2.83 × 10⁻³ |
| Microtubule organizing center organization (GO:0031023) | 2.16 | 1.22 × 10⁻⁴ | 8.91 × 10⁻³ |
| response to UV (GO:0009411) | 2.05 | 1.53 × 10⁻⁵ | 1.47 × 10⁻³ |
| Response to ionizing radiation (GO:0010212) | 1.94 | 1.00 × 10⁻⁴ | 7.49 × 10⁻³ |

CLR: conditional logistic regression; FE: fold enrichment; DFR: false discovery rate

*Top significantly enriched GO annotations were defined using a Q–Q plot ranking of fold enrichment values. The full list of significantly enriched gene ontology annotations is reported in Additional file 13: Table S7a

Nevertheless, we acknowledge several potential limitations of the study that should be considered in interpreting our results. First, even if a fractionated regimen of IRs seems to be the more adapted experimental design to assess the effect of adaptive epigenome alterations to radiation-induced cellular stress, it remains that a higher cumulative dose (> 10 Gy) could induce a more striking epigenome signature associated with IRs and should be investigated in future experiments. Second, we did not assess and quantify the effect of IRs at the cellular level by using a surrogate biomarker to estimate DNA damage [49]. Third, even if our hypothesis on epigenome modifications in the setting of IR exposure was based on DNA methylation alterations, the role of histone modification and chromatin dynamics (e.g., H3K4me3 signature) could not be ruled out and deserves further investigation [50]. In our study, we did not perform methylation profiles on human cancer samples before and after IR exposure for several reasons. First, the EpiMet project received...
centrosome duplication (GO:0051298)
centrosome cycle (GO:0007098)
peripheral nervous system development (GO:0007422)
microtubule organizing center organization (GO:0031023)
response to UV (GO:0009411)
response to ionizing radiation (GO:0010212)

Fig. 7 Q–Q plot for the top enriched gene ontology annotations on CpG probes with beta regression coefficient values > 200 in association with ionizing radiations using conditional logistic regression EWAS on the methionine dependency phenotype

| GO biological process complete                                                                 | CLR-EWAS for the methionine dependency phenotype (MeWo-LC1 vs. MeWo) |
|-----------------------------------------------------------------------------------------------|---------------------------------------------------------------------|
| Positive regulation of protein targeting to mitochondrion (GO:1903955)                        | FE*: 2.00  P-value: 1.03 x 10⁻³  FDR, P-value: 4.57 x 10⁻² |
| Regulation of protein targeting to mitochondrion (GO:1903214)                                | FE*: 2.60  P-value: 5.84 x 10⁻⁴  FDR, P-value: 2.87 x 10⁻² |
| Mitotic metaphase plate congression (GO:0007080)                                             | FE*: 2.60  P-value: 5.84 x 10⁻⁴  FDR, P-value: 2.87 x 10⁻² |
| Embryonic digit morphogenesis (GO:0042733)                                                  | FE*: 2.51  P-value: 4.70 x 10⁻⁴  FDR, P-value: 2.40 x 10⁻² |
| Metaphase plate congression (GO:0051310)                                                    | FE*: 2.47  P-value: 5.38 x 10⁻⁴  FDR, P-value: 2.67 x 10⁻² |
| Positive regulation of establishment of protein localization to mitochondrion (GO:1903749)   | FE*: 2.40  P-value: 9.12 x 10⁻⁴  FDR, P-value: 4.19 x 10⁻² |
| Mitotic G1 DNA damage checkpoint signaling (GO:0031571)                                      | FE*: 2.35  P-value: 4.65 x 10⁻⁴  FDR, P-value: 2.38 x 10⁻² |
| Regulation of establishment of protein localization to mitochondrion (GO:1903747)            | FE*: 2.30  P-value: 3.61 x 10⁻⁴  FDR, P-value: 1.91 x 10⁻² |
| Intrinsic apoptotic signaling pathway in response to DNA damage (GO:0008630)                | FE*: 2.30  P-value: 6.77 x 10⁻⁴  FDR, P-value: 3.24 x 10⁻² |
| Mitotic G1/S transition checkpoint signaling (GO:0044819)                                    | FE*: 2.30  P-value: 5.24 x 10⁻⁴  FDR, P-value: 2.62 x 10⁻² |
| Protein N-linked glycosylation (GO:0006487)                                                 | FE*: 2.30  P-value: 6.84 x 10⁻⁴  FDR, P-value: 3.25 x 10⁻² |
| Mitotic sister chromatid segregation (GO:0000070)                                            | FE*: 2.20  P-value: 4.52 x 10⁻⁵  FDR, P-value: 3.31 x 10⁻³ |
| Intrinsic apoptotic signaling pathway (GO:0097193)                                           | FE*: 2.11  P-value: 1.65 x 10⁻⁵  FDR, P-value: 1.43 x 10⁻³ |
| Negative regulation of G1/S transition of mitotic cell cycle (GO:2000134)                  | FE*: 2.05  P-value: 3.93 x 10⁻⁴  FDR, P-value: 2.05 x 10⁻² |
| G1/S transition of mitotic cell cycle (GO:0000082)                                          | FE*: 2.05  P-value: 6.21 x 10⁻⁴  FDR, P-value: 3.00 x 10⁻² |
| Mitotic cell cycle checkpoint signaling (GO:0007093)                                         | FE*: 2.03  P-value: 2.85 x 10⁻⁵  FDR, P-value: 2.26 x 10⁻³ |
| Mitotic DNA damage checkpoint signaling (GO:0044773)                                         | FE*: 2.02  P-value: 3.85 x 10⁻⁴  FDR, P-value: 2.02 x 10⁻² |
| Cell cycle G1/S phase transition (GO:0044843)                                               | FE*: 2.01  P-value: 9.98 x 10⁻⁴  FDR, P-value: 4.47 x 10⁻² |
| Mitotic DNA integrity checkpoint signaling (GO:0044774)                                       | FE*: 2.01  P-value: 3.16 x 10⁻⁴  FDR, P-value: 1.73 x 10⁻² |

CLR: conditional logistic regression; FE: fold enrichment; DFR: false discovery rate

*Top significantly enriched GO annotations were defined using a Q–Q plot ranking of fold enrichment values. The full list of significantly enriched gene ontology annotations is reported in Additional file 13: Table S7b
regulatory authorizations from the ethics committee of the University of Lorraine to perform analyses on four cell lines representative of three cancer models (HCC, melanoma, and glioblastoma). Second, we developed the EpiMet project to assess the influence of the methionine dependency phenotype on the effect of IRs on the DNA methylome landscape. Methionine dependency is defined as the ‘inability of cells to grow when methionine is replaced in culture medium by its metabolic precursor homocysteine’ [6]. According to this definition, establishing a methionine dependency phenotype is possible through in vitro testing using cell culture models and methionine-free culture media. In vivo strategies of methionine restriction are not efficient and decrease serum methionine by only 40 to 50% [51], which is not sufficient for obtaining complete methionine deprivation. In this setting, the use of methioninase-based strategies for methionine deprivation on xenografted nude mice models could be considered as part of a future development of our research framework [51, 52]. Third, according to international guidelines, IRs are performed after surgery or in definitive intent in glioblastoma, melanoma, or HCC. Thus, the interventions to collect fresh tissues of irradiated tumors would be difficult to defend in an interventional clinical trial.

In conclusion, the present study unraveled shared epigenomic adaptive mechanisms in response to IRs using in vitro models of epidemiologically leading cancerous diseases. These mechanisms are related to cell cycle and division, responses to IR, sustained angiogenesis, tissue invasion, and metastasis. Our results pave the way toward a future research agenda regarding the epigenomic correlates of radioresistance, the development of a clonal selection of radiation-resistant cells, and tumor relapse. Future experimental designs will help better understand the long-term effect of chronic cellular stress on initiating and maintaining epigenetic modifications that could initiate and perpetuate a radioresistance phenotype and its interaction with methionine dependency as a hallmark of metabolic adaptation in cancer.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13148-021-01199-y.

Additional file 1: Figure S1. Quality control regarding the genome-wide distribution of the CpG probes according to their β value. All DNA methylome profiles had a beta distribution and passed the quality criteria.

Additional file 2: Figure S2. 3-D plot using the three top eigenvectors (EV1, EV2, EV3) derived from the primary component analysis on the genome-wide methylome landscape of the studied cell lines, according to study conditions: ‘Baseline’ and ‘End_No irradiation.’

Additional file 3: Figure S3. 2-D plot using the two top eigenvectors (EV1, EV2) derived from the primary component analysis on the genome-wide methylome landscape of the studied cell lines. Cell lines are indicated using elliptical shapes. Study conditions are indicated using the color code (green: Baseline; blue: End_No irradiation; and red: End_Irradiation).

Additional file 4: Table S1a. Results from the epigenome-wide association study that assessed the effect of ionizing radiations on the DNA methylation profile comparing “End_Irradiation” vs. “End_No irradiation or Baseline” conditions.

Fig. 8 Q–Q plot for the top enriched gene ontology annotations on CpG probes with beta regression coefficient values < —200 in association with ionizing radiations using conditional logistic regression EWAS on the methionine dependency phenotype.
Additional file 5: Table S1b. Results from the epigenome-wide association study that assessed the effect of ionizing radiations on the DNA methylation profile comparing "End_Irradiation" vs. "End_No irradiation" conditions.

Additional file 6: Table S2. Results from the epigenome-wide association study that assessed the effect of ionizing radiations on the DNA methylation profile comparing "End_Irradiation" vs. "End_No irradiation or Baseline" conditions in the HepG2 cell line.

Additional file 7: Table S3. Results from the epigenome-wide association study that assessed the effect of ionizing radiations on the DNA methylation profile comparing "End_Irradiation" vs. "End_No irradiation or Baseline" conditions in the MeWo-LC1 cell line.

Additional file 8: Table S4. Results from the epigenome-wide association study that assessed the effect of ionizing radiations on the DNA methylation profile comparing "End_Irradiation" vs. "End_No irradiation or Baseline" conditions in the U251 cell line.

Additional file 9: Table S5. Results from the epigenome-wide association study that assessed the effect of ionizing radiations on the DNA methylation profile comparing "End_Irradiation" vs. "End_No irradiation or Baseline" conditions in the MeWo cell line.

Additional file 10: Figure S4. Epi-Manhattan plot reporting the results of the conditional logistic regression epigenome-wide association study that compared "End_Irradiation" vs. (Baseline/End_No irradiation) according to the methionine dependency phenotype.

Additional file 11: Tables S6. Results from enrichment analyses that used the CpG probes exhibiting a difference of β values >0.1 (a) or <0.1 (b), considering all cell lines. Results from enrichment analyses that used the CpG probes exhibiting a difference of β values >0.1 in HepG2 (c), MeWo (d), MeWo-LC1 (e), and U251 (f). Results from enrichment analyses that used the CpG probes exhibiting a difference of β values <0.1 in HepG2 (g), MeWo (h), MeWo-LC1 (i), and U251 (j).

Additional file 12: Figure S5. Venn diagram illustrating the shared gene ontology annotation pathways between HepG2 and MeWo-LC1 cell lines associated with CpG probes with an increased methylation level and HepG2, MeWo-LC1, and U251 cell lines associated with CpG probes with a decreased methylation level.

Additional file 13: Table S7. Results from enrichment analyses that used the CpG probes with beta regression coefficient values >200 (a) and <200 (b) in conditional logistic regression EWAS that compared methionine-dependent MeWo-LC1 cells to their non-methionine dependent mother cells MeWo.

Acknowledgements

We warmly thank Ms. Aurélie Robert for their kind support in the cell culture facility of the INSERM unit UMR_S 1256 NGERE.

Authors’ contributions

(according to CRediT statement) YS was involved in methodology, validation, formal analysis, writing—original draft preparation, visualization, and supervision; CC, PR, and LB were involved in investigation, resources, and writing—review and editing. JR, AJ, SH, and AF were involved in investigation, resources, and writing—review and editing; JLG was involved in conceptuation, resources, and writing—review and editing; AO was involved in resources, and writing—review and editing, supervision, project administration, and funding acquisition; AO was involved in resources, and writing—review and editing, supervision, project administration, and funding acquisition. All authors read and approved the final manuscript.

Funding

The EpiMet project received grants from La Ligue Contre le Cancer (Grand Est/Bourgogne Franche Comté, France) and from the University of Lorraine (Pôle Biologie Médecine Santé, AAP-BMS_003_211).

Availability of data and materials

Data are available for use in collaborative studies to researchers upon reasonable request (abderrahim.oussalah@univ-lorraine.fr; jean-louis.gueant@univ-lorraine.fr). Data will be provided following the review and approval of a research proposal (including a statistical analysis plan) and the completion of a data-sharing agreement. Responses to the request for the raw data will be judged by the IRB of INSERM UMR_S 1256.

Declarations

Ethics approval and consent to participate

The EpiMet project was declared at the University of Lorraine (Biology, Medicine, and Health Research Pole) and registered under the ID #AAP-BMS_003_211.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 INSEER, UMR_S1256, NGERE (Nutrition, Genetics, and Environmental Risk Exposure), Faculty of Medicine of Nancy, University of Lorraine, 9 Avenue de la Forêt de Haye, 54000 Vandœuvre-lès-Nancy, France. 2 Department of Molecular Medicine and Personalized Therapeutics, Department of Biochemistry, Molecular Biology, Nutrition, and Metabolism, University Hospital of Nancy, 54000 Vandœuvre-lès-Nancy, France. 3 Reference Center for Inborn Errors of Metabolism (ORPHANET7872), University Hospital of Nancy, 54000 Vandœuvres-lès-Nancy, France. 4 Lorraine Institute of Oncology, 54000 Nancy, France. 5 CNRS, UMR_7039, CRAN (Centre de Recherche en Automatique de Nancy), Faculty of Medicine of Nancy, University of Lorraine, 54000 Vandœuvre-lès-Nancy, France. 6 UMR_7365, IMoPa (Ingenierie Moléculaire Et Ingénierie Artificielle), Faculty of Medicine of Nancy, CNRS-UL, University of Lorraine, 54000 Vandœuvre-lès-Nancy, France.

Received: 16 July 2021 Accepted: 12 November 2021

Published online: 01 December 2021

References

1. Jones PA, Issa JP, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev Genet. 2016;17(10):630–41.
2. Kinnaird A, Zhao S, Wellen KE, Michelakis ED. Metabolic control of epigenetics in cancer. Nat Rev Cancer. 2016;16(11):694–707.
3. Nebbioso A, Tambaro FP, Dell’Aversana C, Altucci L. Cancer epigenetics: Moving forward. PLoS Genet. 2018;14(6):e1007362.
4. Izzo LT, Affronti HC, Wellen KE. The bidirectional relationship between cancer epigenetics and metabolism. Annu Rev Cancer Biol. 2021;5(1):235–57.
5. Keyvani-Ghamarsi S, Khorsandi K, Rasul A, Zaman MK. Current understanding of epigenetics mechanism as a novel target in reducing cancer stem cells resistance. Clin Epigenet. 2021;13(1):120.
6. Cavuoto P, Fenech MF. A review of methionine dependency and the role of methionine restriction in cancer growth control and life-span extension. Cancer Treat Rev. 2012;38(6):726–36.
7. Hoffman RM. Development of recombinant methioninase to target the general cancer-specific metabolic defect of methionine dependence: a 40-year odyssey. Exp Open Biol Ther. 2015;15(1):121–31.
8. Wang Z, Yip LY, Lee JHJ, Wu Z, Chew HY, Chong PKW, Teo CC, Ang HY, Peh KE, Yuan J, et al. Methionine is a metabolic dependency of tumor-initiating cells. Nat Med. 2019;25(5):825–37.
9. Aggarwal A, Lewison G, Rodin D, Zietman A, Sullivan R, Lievens Y. Radiation therapy research: a global analysis 2001–2015. Int J Radiat Oncol Biol Phys. 2018;101(4):767–78.
10. Cabrera AR, Kirkpatrick JP, Fiveash JB, Shih HA, Koay EJ, Lutz S, Pett J, Chao ST, Brown PD, Vogelbaum M, et al. Radiation therapy for glioblastoma: executive summary of an American Society for Radiation
Oncology evidence-based clinical practice guideline. Pract Radiat Oncol. 2016;6(4):217–25.

11. Farrell C, Shi W, Bodman A, Olson JJ. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma. J Neurooncol. 2020;150(2):269–359.

12. Minniti G, Niyazi M, Alongi F, Navarria P, Belica C. Current status and recent advances in reirradiation of glioblastoma. Radiat Oncol (London, England). 2021;16(1):36.

13. Durand-Labrunie J, Baumann AS, Ayav A, Laurent V, Boleslawski E, Cattan S, Bogart E, Le Deley MC, Steen V, Larcornere T, et al.4. 35. Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):853–55.

14. Miousse IR, Kutanzi KR, Koturbash I. One-carbon metabolism and ionizing radiation: a pooled analysis of an Asian liver radiation therapy group study. Int J Radiat Oncol Biol Phys. 2021;109(2):464–73.

15. Kim N, Cheng J, Huang WY, Kimura T, Zeng ZC, Lee VHF, Kay CS, Seong J. Dose-response relationship in stereotactic body radiation therapy for hepatocellular carcinoma: a pooled analysis of an Asian liver radiation therapy group study. Int J Radiat Oncol Biol Phys. 2021;109(2):464–73.

16. Sokolov MV, Panyutin IV, Neumann RD. Unraveling the global microRNA expression. PLoS ONE. 2009;4(7):e6377.

17. Snijders AM, Marchetti F, Bhagatgar S, Duro N, Han J, Hu Z, Mao JH, Gray JW, Wyrobeck AJ. Genetic differences in transcript responses to low-dose ionizing radiation identify tissue functions associated with breast cancer susceptibility. PLoS ONE. 2012;7(10):e45394.

18. Sokalov MV, Panyutin IV, Neumann RD. Unraveling the global microRNAome responses to ionizing radiation in human embryonic stem cells. PLoS ONE. 2012;7(1):e31028.

19. Liu T, Du X, Sheng X. Gene expression changes after ionizing radiation in endothelial cells derived from human endometrial cancer-preliminary outcomes. Arch Gynecol Obstet. 2014;289(6):1315–23.

20. Rashv-Ekhte S, Wartnitz H, Elkon R, Kupershmidt A, Chroboczy P, Aza P, Amstislavsky V, Sultan M, Safer H, Niefeld W, et al. Parallel profiling of the transcriptome, circrome, and epigenome in the cellular response to ionizing radiation. Sci Signal. 2014;7(325):rs3.

21. Miousse IR, Tobacyk J, Melnyk S, James SJ, Cheema AK, Boerma M, Hauer-Jensen M, Koturbash I. One-carbon metabolism and ionizing radiation: a multifaceted interaction. Biomol Concepts. 2017;8(6):83–92.

22. Smits KM, Melotte V, Niessen HE, Dubois L, Oberije C, Troost EG, Starmans MH, Boutrous PC, Vooijs M, van Engeland M, et al. Epigenetics in radiotherapy: where are we heading? Radiother Oncol J Eur Soc Therap Radiol Oncol. 2021;159, 48–59.

23. Oussalah A, Avogbe PH, Guyot E, Chery C, Guerant-Rodriguez RM, Ganne-Carrie N, Cobat A, Moradpour D, Nalpas B, Negro F, et al. BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease. Onco-target. 2016. https://doi.org/10.18632/oncotarget.11327.

24. Wolffe AP, Matzke MA. Epigenetics: regulation through repression. Science. 1999;286(5439):481–6.

25. Chen Z, Li S, Subramaniam S, Shyy JY, Chien S. Epigenetic regulation: a new frontier for biomedical engineers. Annu Rev Biomed Eng. 2017;19:205–19.

26. Dor Y, Cedar H. Principles of DNA methylation and their implications for biology and medicine. Lancet. 2018;392(10149):777–86.

27. Feinberg AP. The key role of epigenetics in human disease prevention and mitigation. N Engl J Med. 2018;378(14):1323–34.

28. Gueant JL, Chery C, Oussalah A, Nadaf J, Coelho D, Josse T, Flayac J, Robbert A, Kosinski I, Gastin L, et al. APRDX1 mutant allele causes a MAMACH secondary epimutation in cBcR patients. Nat Commun. 2018;9(1):67.

29. Doerfler W, Weber S, Naumann A. Inheritable epigenetic response towards foreign DNA entry by mammalian host cells: a guardian of genomic stability. Epigenetics. 2018;13(12):1141–53.

30. Huang N, Pei X, Lin W, Chiu JF, Tao T, Li G. DNA methylation of a non-CpG island promoter represses NON1 expression in rat arsenic-transformed lung epithelial cells. Acta Biochim Biophys Sin. 2016;50(8):733–9.

31. Mayorga L, Salassa BH, Marquez DM, Loos MA, Eiroa HD, Lubieniecki F, García Samartino C, Romano PS, Roque M. Mitochondrial stress triggers a pro-survival response through epigenetic modifications of nuclear DNA. Cell Mol Life Sci CMLS. 2019;76(3):397–417.

32. Antwi DA, Gabbarra KM, Lancaster WD, Ruden DM, Zieleske SJ. Radiation-induced epigenetic DNA methylation modification of radiation-response pathways. Epigenetics. 2013;8(8):839–48.

33. Chen X, Liu L, Mims J, Punska EC, Williams KE, Zhao W, Arcaro KF, Tsang AW, Zhou X, Furdi CM. Analysis of DNA methylation and gene expression in radiation-resistant head and neck tumors. Epigenetics. 2015;10(6):545–61.

34. Danielsson A, Barreau K, Kling T, Tisel M, Carell H. Accumulation of DNA methylation alterations in paediatric glioma stem cells following fractionated dose irradiation. Clin Epigenet. 2020;12(1):21.

35. Pernot E, Hall J, Baatout S, Benotmane MA, Blanchardon E, Bouffier S, El Sahireh G, Gomolka M, Guertler A, Harms-Ringdahl M, et al. Ionizing radiation biomarkers for potential use in epidemiological studies. Mutat Res. 2012,75(2):258–86.

36. Dai Z, Mentch SJ, Gao X, Nichenametla SN, Locasale JW. Methionine metabolism influences genomic architecture and gene expression through H3K4me3 peak width. Nat Commun. 2018;9(1):1955.

37. Lu WC, Saha A, Yan W, Garrison K, Lamb C, Pandey R, Irani S, Lodig L, Lu X, Tzian D, Imai K, Hijichi G, Sugisawa N, et al. Recombinant methioninase overcomes colorectal-cancer liver metastasis resistance to the combination of tumorigenicity and methionine dependence. Mol Genet Metab. 2009;96(4):261–7.

38. Mi H, Muruganujan A, Casagrande JT, Thomas PD. Large-scale gene function analysis with the PANTHER classification system. Nat Protoc. 2017;12(6):1551–66.

39. Supek F, Bosnjak M, Skurcna N, Smuc T. REVIGO summarizes and visualizes long lists of gene ontology terms. PLoS ONE. 2011;6(7):e21800.

40. Sun H, Fregly J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.

41. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–27.

42. Bruij J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):853–55.
5-fluorouracil and oxaliplatinum in a patient-derived orthotopic xenograft mouse model. Anticancer Res. 2019;39(9):4667–71.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.